<DOC>
	<DOCNO>NCT00071097</DOCNO>
	<brief_summary>The purpose study determine effectiveness , safety , tolerability ( well body stand drug ) investigational protease inhibitor ( PI ) call TMC114 give low dose ritonavir .</brief_summary>
	<brief_title>TMC114-C202 : A Study Safety , Efficacy , Tolerability TMC114 Low Dose Ritonavir HIV-1 Infected Patients</brief_title>
	<detailed_description>A phase II randomize , control , partially blind , trial investigate dose response TMC114/RTV HIV-1 infect patient previously receive three licensed class HIV antiviral drug ( know nucleoside reverse transcriptase inhibitor ( NRTI ) , nonnucleoside reverse transcriptase inhibitor ( NNRTI ) protease inhibitor ( PI ) ) , stable PI-containing regimen include NNRTI may eligible participate . Four dose TMC-114/ritonavir study . 300 patient United States Puerto Rico participate . The duration study 96 week . Randomize one 4 treatment group ( TMC114/RTV : 400/100 mg qd ; 800/100mg qd ; 400/100mg bid ; 600/100 bid ) control arm 24 48 wks . Optimal dose ( TMC114/RTV 600/100mg bid ) open label portion study . The trial extend include 144Wks treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Male female , age 18 year older Documented HIV1 infection Stable PI regimen least 8 week prior screen Plasma viral load screening 1000 HIV1 RNA copies/ml Prior use 1 NRTI least 3 month Prior use one NNRTIs part fail regimen At least 1 primary PI mutation define IAS guideline Treatment least 1 PI total least 3 month Patient give informed consent Presence currently active AIDS defining illness except stable cutaneous Kaposi 's Sarcoma Wasting syndrome due HIV infection Current past history alcohol and/or drug abuse , investigator 's opinion , would compromise subject 's safety compliance study protocol procedure NNRTI part therapy screen Patients treatment interruption screen Patients investigational antiretroviral therapy part regimen screen use nonantiretroviral investigational agent 90 day prior screen Hepatitis A , B , C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>TMC114</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Safety efficacy</keyword>
	<keyword>TMC114-C211</keyword>
</DOC>